KR19980065189A - New synthetic intermediates of moussecon and preparation method thereof - Google Patents

New synthetic intermediates of moussecon and preparation method thereof Download PDF

Info

Publication number
KR19980065189A
KR19980065189A KR1019970000044A KR19970000044A KR19980065189A KR 19980065189 A KR19980065189 A KR 19980065189A KR 1019970000044 A KR1019970000044 A KR 1019970000044A KR 19970000044 A KR19970000044 A KR 19970000044A KR 19980065189 A KR19980065189 A KR 19980065189A
Authority
KR
South Korea
Prior art keywords
compound
tosyl
organic solvent
catalyst
followed
Prior art date
Application number
KR1019970000044A
Other languages
Korean (ko)
Other versions
KR100226622B1 (en
Inventor
박대규
Original Assignee
박대규
조선무약 합자회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 박대규, 조선무약 합자회사 filed Critical 박대규
Priority to KR1019970000044A priority Critical patent/KR100226622B1/en
Publication of KR19980065189A publication Critical patent/KR19980065189A/en
Application granted granted Critical
Publication of KR100226622B1 publication Critical patent/KR100226622B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms

Abstract

본 발명은, 무스콘(Muscone)의 신규합성중간체 및 그의 제조방법에 관한 것으로, 하기 구조식(Ⅰ) 또는 (Ⅱ)를 갖는다.The present invention relates to a novel synthetic intermediate of Muscone and a method for producing the same, and has the following structural formula (I) or (II).

(R1=Methyl, Mesyl, Benzyl, Tosyl,)(R 1 = Methyl, Mesyl, Benzyl, Tosyl,)

상기 구조식(Ⅰ) 또는 (Ⅱ)의 신규화합물이며, 무스콘의 전구물질로서 이들로부터 엘 또는 디-무스콘을 고수율, 고순도로 제조할 수 있는 특장점이 있다.It is a novel compound of the above-mentioned structural formula (I) or (II), and has the advantage of being able to manufacture L or di-muscon with high yield and high purity from these as a precursor of mousse cone.

Description

무스콘의 신규합성중간체 및 그의 제조방법New synthetic intermediates of moussecon and preparation method thereof

본 발명은 무스콘(Muscone)의 신규합성중간체 및 그의 제조방법에 관한 것으로, 특히 하기 구조식(Ⅰ)의 디-3-메칠-시클로펜타데칸-1-온, 1,4-디-0-알킬 또는 아릴-2,3-D-스레이톨 케탈과, 구조식(Ⅱ)의 엘-3-메칠-시클로펜타데칸-1-온, 1,4-디-0-알킬 또는 아릴-2,3-D-스레이톨 케탈 및 그들의 제조방법에 관한 것이다.The present invention relates to a novel synthetic intermediate of Muscone and a method for preparing the same, in particular di-3-methyl-cyclopentadecan-1-one of the following structural formula (I), 1,4-di-0-alkyl Or aryl-2,3-D- stolitol ketal, and El-3-methyl-cyclopentadecan-1-one of formula (II), 1,4-di-0-alkyl or aryl-2,3-D It relates to a Sreitol ketal and a method for producing the same.

(R1=Methyl, Mesyl, Benzyl, Tosyl,)(R 1 = Methyl, Mesyl, Benzyl, Tosyl,)

상기 구조식을 갖는 화합물(Ⅰ), (Ⅱ)는 디-3-메칠-시클로펜타데칸-1-온(Ⅲ, 이하 디-무스콘(d-Muscone)이라 함)과, 엘-3-메칠-시클로펜타데칸-1-온(Ⅳ), 이하, 엘-무스콘(1-Muscone)이라 함)의 전물질로써 신규 합성중간체이며, 이들은 뇌질환 및 심순환계등에 작용되는 의약품 원료를 유용하게 사용될 전마이다.Compounds (I) and (II) having the above structural formulas include di-3-methyl-cyclopentadecan-1-one (III, hereinafter referred to as d-Muscone) and L-3-methyl- As a whole substance of cyclopentadecane-1-one (IV), hereinafter referred to as L-muscone, it is a novel synthetic intermediate, which is useful for the use of pharmaceutical raw materials for brain diseases and cardiovascular system. Mya.

지금까지 화합물(Ⅲ)과 (Ⅳ)를 제조하기 위해 몇가지의 방법들이 알려져 있으나 그 제조방법의 대부분은 수율이 매우 낮고 제조원가가 고가이거나 반응조건이 까다롭고 복잡하여 공업화 또는 대량생산에는 적합하지 못한 실정이었다.Several methods have been known for the preparation of compounds (III) and (IV), but most of the production methods are not suitable for industrialization or mass production due to the low yield, high production cost, and difficult and complicated reaction conditions. It was.

(참조:1Stallberg, S.S Arkiz. Kemi. 3, 517, 1951,2Nelson, K.A. and Mash, E.A. J. Org. Chem. 51, 2721, 1986,3H.Nohira J. Org. Chem. 52, 1630, 1987,4Tanaka, K. and Uscio, H. J. Chem. Soc. Chem. Commun. 1, 101, 1991)( 1 Stallberg, SS Arkiz. Kemi. 3, 517, 1951, 2 Nelson, KA and Mash, EAJ Org. Chem. 51, 2721, 1986, 3 H. Nohira J. Org. Chem. 52, 1630, 1987 , 4 Tanaka, K. and Uscio, HJ Chem. Soc.Chem.Commun. 1, 101, 1991)

따라서, 본 발명자는 상기와 같은 종래의 기술상의 문제점을 해결하기 위해 10여년에 걸쳐 연구하여 온 결과 화합물(Ⅰ), (Ⅱ)가 화합물(Ⅲ)과 (Ⅳ)를 대량생산할 수 있는 신규 합성중간체로써 유용함을 발견하고 화합물(Ⅰ), (Ⅱ) 및 그들의 제조방법을 강구하여 본건 발명을 완성하게 되었다.Therefore, the present inventors have studied over 10 years to solve the above technical problems, and as a result, a novel synthetic intermediate capable of mass-producing compounds (III) and (IV) can be produced. This invention was found to be useful, and the present invention was completed by finding compounds (I) and (II) and their preparation methods.

그러므로, 본 발명의 목적은 고수율, 고순도 및 낮은 가격으로 제조한 하기 화합물(Ⅴ)로부터 화합물(Ⅰ)과 (Ⅱ)의 혼합물을 제조하는 방법 및 이들의 혼합물로부터 신규 합성중간체인 화합물(Ⅰ), (Ⅱ) 및 그들의 제조방법을 제공하는 것이다.Therefore, it is an object of the present invention to prepare a mixture of compounds (I) and (II) from the following compound (V) prepared in high yield, high purity and low price and compound (I) which is a novel synthetic intermediate from the mixture thereof. , (II) and a method for producing the same.

이하 본 발명을 구체적으로 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail.

(R=Methyl, Ethyl)(R = Methyl, Ethyl)

(R1=Methyl, Mesyl, Benzyl, Tosyl,)(R 1 = Methyl, Mesyl, Benzyl, Tosyl,)

촉매존재하에서, 디엘-무스콘(Ⅴ)과 케탈화제와의 케탈화반응으로 디메칠 디엘-무스콘 케탈(Ⅵ)을 제조한 다음, (Ⅵ)화합물을 1,4-디-0-알킬 또는 아릴-2,3-D-스테이톨(Ⅶ)과의 케탈교환반응으로 화합물(Ⅰ)과 (Ⅱ)의 혼합물을 제조하여 이 혼합물로부터 재결정법, 크로마토그래피법등의 방법을 이용하여 각각의 화합물(Ⅰ)과 (Ⅱ)를 제조한다.In the presence of a catalyst, dimethyl-diesel-muscon ketal (VI) was prepared by ketalization of DL-muscon (V) with a ketalizing agent, and then (VI) compound was converted into 1,4-di-0-alkyl or A mixture of compounds (I) and (II) was prepared by ketal exchange with aryl-2,3-D-statitol, and from each mixture was prepared by recrystallization, chromatography, or the like. Prepare I) and (II).

본 발명을 좀더 상세히 설명하면 다음과 같다.The present invention will be described in more detail as follows.

케탈화반응은 촉매로써 몬트몰리노나이트 K-10과 케탈화제인 CH(OR)3, (R=Me, Et)를 유기용매속에서 1시간동안 교반하여 준 후 미리 유기용매에 녹인 디엘-무스콘(Ⅴ)을 첨가하고 40분-90분동안 교반한 다음, 감압여과하여 얻은 몬트몰리노나이트 K-10의 잔사를 유기용매로 충분히 세척한 후 상기 유기용매와 합하고 감압유거하여 화합물(Ⅵ)을 제조한다.The ketalization reaction was carried out by stirring montmolinonite K-10 as a catalyst and the chelating agent CH (OR) 3 , (R = Me, Et) in an organic solvent for 1 hour and then dissolving DL-mu in an organic solvent. After adding scone (V) and stirring for 40 minutes to 90 minutes, the residue of montmolininite K-10 obtained by filtration under reduced pressure was sufficiently washed with an organic solvent, combined with the organic solvent, and distilled under reduced pressure to give a compound (VI). To prepare.

이때, 촉매로써는 건조된 HCl, TsOH, NH4Cl, PhSO2NHOH, NaOH, La(또는 Ce, Nd, Er, Yb)Cl3, 산성 이온교환수지, 몬트몰리노나이트 K-10 등을 사용할 수 있으며, 그 중에서 몬트몰리노나이트 K-10가 가장 바람직하다.At this time, the catalyst may be dried HCl, TsOH, NH 4 Cl, PhSO 2 NHOH, NaOH, La (or Ce, Nd, Er, Yb) Cl 3 , acidic ion exchange resin, montmolinonit K-10, etc. Among them, montmolinonit K-10 is most preferred.

몬트몰리노나이트 K-10의 사용량은 화합물(Ⅴ)에 대하여 중량비로 1∼4배를 사용할 수 있으며, 그 중에서 2∼3배를 사용하는 것이 가장 바람직하다.The use amount of montmolinoite K-10 can be used 1 to 4 times by weight relative to compound (V), and it is most preferable to use 2 to 3 times.

한편, 케탈화제로는 MeOH, MeOH/(MeO)4Si, Me2SO4/MeOH CH(OEt)3, CH(OMe)3등이 사용되는데, 그 중에서 CH(OEt)3또는 CH(OMe)3를 사용하는 것이 가장 바람직하다.Meanwhile, as the ketalizing agent, MeOH, MeOH / (MeO) 4 Si, Me 2 SO 4 / MeOH CH (OEt) 3 , CH (OMe) 3, and the like are used, among which CH (OEt) 3 or CH (OMe) Most preferably, 3 is used.

CH(OMe)3의 사용량은 화합물(Ⅴ)에 대하여 몰비율로 2-10배를 사용하여 반응시킬 수 있으며, 그 중에서 4∼8배를 사용하는 것이 가장 바람직하다.The amount of CH (OMe) 3 can be reacted with 2-10 times in molar ratio with respect to compound (V), of which 4-8 times are most preferred.

또한, 유기용매로는 극성용매인 메탄올, 에탄올, 프로필알콜 등이 사용되고, 무극성용매로는 노르말-헥산, 사염화탄소 등이 사용되며, 그 중에서 노르말-헥산을 사용하는 것이 가장 바람직하다.In addition, as the organic solvent, methanol, ethanol, propyl alcohol, and the like, which are polar solvents, are used. As the nonpolar solvent, normal-hexane and carbon tetrachloride are used, and among them, normal-hexane is most preferable.

반응온도는 환류 온도 또는 실온에서 행할 수 있으며, 특히 실온에서 실시하는 것이 가장 바람직하다.The reaction temperature can be performed at reflux or at room temperature, and most preferably at room temperature.

케탈교환반응은 산촉매하에서, 화합물(Ⅵ)을 무수벤젠에 용해시킨 다음 화합물(Ⅶ)을 가하고 가열하여 용해시킨 다음 1∼2시간동안 가열하거나, 또는 화합물(Ⅵ)을 유기용매에 용해시킨 다음 화합물(Ⅶ)을 가하여 실온에서 1∼2시간동안 교반하여 화합물(Ⅰ)과 (Ⅱ)의 혼합물을 제조한다.The ketal exchange reaction is carried out by dissolving compound (VI) in anhydrous benzene under acid catalyst, adding compound (VII), heating to dissolve, and heating for 1-2 hours, or dissolving compound (VI) in organic solvent (I) was added and stirred at room temperature for 1-2 hours to prepare a mixture of compounds (I) and (II).

한편, 촉매를 사용하지 않는 경우에는 벤젠이나 극성 유기용매에 화합물(Ⅵ), (Ⅶ)을 용해시켜 환류시키거나 또는 실온에서 8∼24시간동안 교반한다.On the other hand, when a catalyst is not used, compound (VI) and (iii) are dissolved and refluxed in benzene or a polar organic solvent or stirred at room temperature for 8 to 24 hours.

산촉매로는 트리후루오로보란 이서레이트, 파라톨루엔설폰산, 파라톨루엔설폰산 피리딘 염 등을 사용할 수 있으며, 그 중에서 트리후루오로보란 이서레이트 또는 파라톨루엔설폰산을 사용하는 것이 가장 바람직하고, 그 사용량은 화합물(Ⅴ)에 대하여 0.1∼0.005 몰비율로 사용할 수 있으며, 0.01∼0.03몰 비율로 사용하는 것이 가장 바람직하다.As the acid catalyst, trifuroboroborane isomerate, paratoluenesulfonic acid, paratoluenesulfonic acid pyridine salt, and the like can be used. Among them, trifuroboroborane isate or paratoluenesulfonic acid is most preferably used. It can be used in 0.1-0.005 molar ratio with respect to silver compound (V), It is most preferable to use in 0.01-0.03 molar ratio.

이때, 사용되는 유기용매로는 클로로포름, 디클로로메탄, 에테르, 에탄올, 메탄올 등을 사용할 수 있으며, 이 중에서 디클로로메탄 또는 에테르를 사용하는 것이 가장 바람직하다.In this case, chloroform, dichloromethane, ether, ethanol, methanol, and the like may be used as the organic solvent, and among them, dichloromethane or ether is most preferable.

R1그룹이 토실기인 경우에는, 상기에서 제조한 화합물(Ⅰ)과 (Ⅱ)의 혼합물을 극성용매인 메탄올, 메탄올-클로로포름, 헥산-클로로포름, 석유에테르-클로로포름 등의 혼합액 혹은, 석유에테르, 헥산 등의 무극성 유기용매를 사용하여 재결정 방법에 의하여 화합물(Ⅰ)과 (Ⅱ)를 각각 얻을 수 있으며, 이 중에서 극성용매인 메탄올을 사용하는 경우가 가장 바람직하다.When the R 1 group is a tosyl group, a mixture of compounds (I) and (II) prepared above is mixed with a polar solvent such as methanol, methanol-chloroform, hexane-chloroform, petroleum ether-chloroform, or a petroleum ether or hexane. Compounds (I) and (II) can be obtained by a recrystallization method using a nonpolar organic solvent such as these, and of these, methanol is most preferably used as a polar solvent.

또한, R1그룹이 메칠, 메실, 토실 또는, 벤질기인 경우에는, 상기에서 제조한 화합물(Ⅰ)과 (Ⅱ)의 혼합물을 아세토니트릴-물 혼합액, 클로로포름-헥산 혼합액, 헥산-에틸아세테이트 혼합액을 사용하여 크로마토그래피법(MPLC)를 행하여 화합물(Ⅰ)와 (Ⅱ)의 화합물을 각각 얻을 수 있으며, 이 중에서 아세토니트릴-물 혼합액을 사용하는 것이 가장 바람직하다.In the case where the R 1 group is methyl, mesyl, tosyl or benzyl group, a mixture of the above-mentioned compounds (I) and (II) may be added to the acetonitrile-water mixture, the chloroform-hexane mixture, and the hexane-ethyl acetate mixture. Chromatography (MPLC) can be used to obtain compounds of Compounds (I) and (II), respectively, of which acetonitrile-water mixtures are most preferred.

이때, 칼럼의 규격은 41.4㎜*250㎜를 사용하였으며 유속(ml/분)은 50, 검출기는 자외선 254nm를 사용하였으며, 충진제는 C8, C18을 사용할 수 있으며, 그 중에서 C18을 사용하는 것이 가장 바람직하다.At this time, the size of the column was used 41.4㎜ * 250㎜, flow rate (ml / min) is 50, the detector was UV 254nm, the filler can be C 8 , C 18 can be used, of which C 18 Most preferred.

다음의 실시예를 들어 본 발명을 상세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail with reference to the following examples.

실시예에 의하여 본 발명의 특허청구의 범위가 한정되는 것은 아니다.The scope of the claims of the present invention is not limited by the examples.

[실시예 1]Example 1

디-3-메칠-시클로펜타데칸-1-온 1,4-디-0-토실-2,3-D-스레이콜 케탈[(Ⅰ),R1=Tosyl]과 엘-3-메칠-시클로펜타데칸-1-온 1,4-디-0-토실-2,3-D-스레이톨 케탈[(Ⅱ),R1=Tosyl]의 제조Di-3-methyl-cyclopentadecan-1-one 1,4-di-0-tosyl-2,3-D- flake ketal [(I), R 1 = Tosyl] and L-3-methyl-cyclo Preparation of pentadecane-1-one 1,4-di-0-tosyl-2,3-D- stolitol ketal [(II), R 1 = Tosyl]

질소로 충진된 100ml 1구 플라스크에 몬트몰리노나이트 K-10 25g과 CH(OMe)338ml를 넣고 1시간동안 실온에서 교반한다. 미리 무수헥산 30ml에 용해시킨 디엘-무스콘(Ⅴ) 10.0g을 반응기에 가하고 1.5시간동안 실온에서 교반한 다음 감압여과하고 얻은 몬트몰리노나이트 K-10 잔사를 무수헥산 300ml로 세척하고, 상기 유기용매와 합하여 감압유거하여 얻은 디메칠 디엘-무스콘 케탈(Ⅵ)에 1,4-디-0-토실-2,3-D-스테이톨(Ⅶ, R=tosyl) 18.07g, 디클로로메탄 25ml를 순차적으로 가하고 트리후루오로보란 이서레이트 0.25ml를 가한 다음 실온에서 2시간동안 교반한다.Into a 100 ml one-necked flask filled with nitrogen, 25 g of montmolinoite K-10 and 38 ml of CH (OMe) 3 were added and stirred at room temperature for 1 hour. 10.0 g of DL-muscon (V) dissolved in 30 ml of anhydrous hexane was added to the reactor, stirred at room temperature for 1.5 hours, and filtered under reduced pressure, and the obtained montmolinoite K-10 residue was washed with 300 ml of anhydrous hexane, and the organic 18.07 g of 1,4-di-0-tosyl-2,3-D-stitol (Ⅶ, R = tosyl) and 25 ml of dichloromethane were added to dimethyl DL-muscon ketal (VI) obtained by distillation under reduced pressure in combination with a solvent. The solution was added sequentially, 0.25 ml of trifluorouroborane acrylate was added, followed by stirring at room temperature for 2 hours.

반응액을 디클로로메탄 200ml로 희석시키고 물 100ml, 포화 소금물로 순으로 세척한 다음 황산마그네슘으로 건조하고, 감압유거하여 얻은 미황색 고체 27.12g을 헥산 60ml로 충분히 세척하여 하기 구조식을 갖는 [(Ⅰ), R1=Tosyl]과 [(Ⅱ), R1=Tosyl]의 혼합물 25.24g을 얻었다.The reaction solution was diluted with 200 ml of dichloromethane, washed with 100 ml of water and saturated brine in that order, dried over magnesium sulfate, and 27.12 g of a slightly yellow solid obtained by distillation under reduced pressure was sufficiently washed with 60 ml of hexane [(I), 25.24 g of a mixture of R 1 = Tosyl] and [(II), R 1 = Tosyl] was obtained.

이 혼합물을 메탄올을 사용하여 3회에 걸쳐 재결정하여 미황색고체인 화합물[(Ⅰ), R1=Tosyl]을 9.36g(37%)얻었다.(순도 99%)The mixture was recrystallized three times using methanol to obtain 9.36 g (37%) of a pale yellow solid [(I), R 1 = Tosyl] (purity 99%).

mp; 84.0-85.0℃mp; 84.0-85.0 ℃

1H-NMR(CDCl3, ppm); 1 H-NMR (CDCl 3 , ppm);

7.78(4Htosyl, d, 8.8Hz), 7.35(4Htosyl, d, 8.8Hz), 4.10(4H2'2, m), 3.92(2H1'1, m), 2.46(6Htosyl, s), 1.60-1.06(27Hring, hump), 0.82(3H16, d, 7.0Hz)7.78 (4H tosyl , d, 8.8 Hz), 7.35 (4H tosyl , d, 8.8 Hz), 4.10 (4H 2'2 , m), 3.92 (2H 1'1 , m), 2.46 (6H tosyl , s), 1.60-1.06 (27H ring , hump), 0.82 (3H 16 , d, 7.0 Hz)

13C-NMR(CDCl3, ppm); 13 C-NMR (CDCl 3 , ppm);

Ctosyl:144.98, 144.96, 132.53, 132.50, 129.79, 127. 83, 114.37(C1), 74.72(C1'), 74.40(C1), 68.48(C2'), 68.39(C2), 43.84(C2), 36.67(C15), 36.10(C4), 27.69(C3), 20.67(C16)C tosyl : 144.98, 144.96, 132.53, 132.50, 129.79, 127. 83, 114.37 (C 1 ), 74.72 (C 1 ' ), 74.40 (C 1 ), 68.48 (C 2' ), 68.39 (C 2 ), 43.84 (C 2 ), 36.67 (C 15 ), 36.10 (C 4 ), 27.69 (C 3 ), 20.67 (C 16 )

Cring:27.01, 26.95, 26.61, 26.46, 26.43, 26.18, 25.94, 25.91, 24.82, 21.98. 21.46C ring : 27.01, 26.95, 26.61, 26.46, 26.43, 26.18, 25.94, 25.91, 24.82, 21.98. 21.46

Mass(m/e):650.3(M+), 607.3, 531.1, 481.0, 467.1, 390.0, 369.2, 327.0, 154.8, 90.8, 68.8Mass (m / e): 650.3 (M + ), 607.3, 531.1, 481.0, 467.1, 390.0, 369.2, 327.0, 154.8, 90.8, 68.8

IR(KBr, cm-1):2926, 2856, 1353, 1176, 1099, 978, 939, 858, 815IR (KBr, cm -1 ): 2926, 2856, 1353, 1176, 1099, 978, 939, 858, 815

=-15.67(c 1.0, CHCl3, 100㎜) = -15.67 (c 1.0, CHCl 3 , 100 mm)

상기 화합물[(Ⅰ), R1=Tosyl]을 제조하고 남은 모액으로부터 얻은 화합물을 메탄올을 사용하여 3회 재결정을 실시하여 미황색의 고체인 화합물[(Ⅱ), R1=Tosyl] 7.76g(31%)을 얻었다.The compound [(Ⅰ), R 1 = Tosyl] the preparation and the three times re-crystallized using methanol, the compound obtained from the remaining mother liquor to the compound as a pale yellow solid [(Ⅱ), R 1 = Tosyl] 7.76g (31 %) Was obtained.

(순도 99%)(99% purity)

(Ⅱ), R1=Tosyl(II), R 1 = Tosyl

mp; 91.5-92.5℃mp; 91.5-92.5 ℃

1H-NMR(CDCl3, ppm); 1 H-NMR (CDCl 3 , ppm);

7.77(4Htosyl, d, 8.8Hz), 7.36(4Htosyl, d, 8.8Hz), 4.07(4H2'2, m), 3.97(2H1'1, m), 2.46(6Htosyl, s), 1.65-1.14(27Hring, hump), 0.82(3H16, d, 7.0Hz)7.77 (4H tosyl , d, 8.8 Hz), 7.36 (4H tosyl , d, 8.8 Hz), 4.07 (4H 2'2 , m), 3.97 (2H 1'1 , m), 2.46 (6H tosyl , s), 1.65-1.14 (27H ring , hump), 0.82 (3H 16 , d, 7.0 Hz)

13C-NMR(CDCl3, ppm); 13 C-NMR (CDCl 3 , ppm);

Ctosyl:145.02, 144.99, 132.43, 132.41, 129.84, 129. 82, 127.77, 114.52(C1), 75.00(C1'), 74.45(C1), 68.46(C2'), 68.34(C2), 44.22(C2), 36.59(C15), 35.97(C4), 27.64(C3), 20.86(C16)C tosyl : 145.02, 144.99, 132.43, 132.41, 129.84, 129. 82, 127.77, 114.52 (C 1 ), 75.00 (C 1 ' ), 74.45 (C 1 ), 68.46 (C 2' ), 68.34 (C 2 ) , 44.22 (C 2 ), 36.59 (C 15 ), 35.97 (C 4 ), 27.64 (C 3 ), 20.86 (C 16 )

Cring:27.03, 26.96, 26.57, 26.43, 26.29, 26.09, 25.89, 24.86, 21.78, 21.46,C ring : 27.03, 26.96, 26.57, 26.43, 26.29, 26.09, 25.89, 24.86, 21.78, 21.46,

Mass(m/e):650.3(M+), 607.3, 531.1, 481.0, 467.1, 390.0, 369.2, 327.0, 154.8, 90.8, 68.8Mass (m / e): 650.3 (M + ), 607.3, 531.1, 481.0, 467.1, 390.0, 369.2, 327.0, 154.8, 90.8, 68.8

IR(KBr, cm-1):2927, 2855, 1361, 1180, 1097, 971, 945, 854, 814IR (KBr, cm -1 ): 2927, 2855, 1361, 1180, 1097, 971, 945, 854, 814

=-1.48(c 1.0, CHCl3, 100㎜) = -1.48 (c 1.0, CHCl 3 , 100 mm)

[실시예 2]Example 2

디-3-메칠-시클로펜타데칸-1-온 1,4-디-0-토실-2,3-D-스테이톨 케탈[(Ⅰ), R1=Tosyl]과 엘-3-메칠-시클로펜타데칸-1-온 1,4-디-0-토실-2,3-D-스테이톨 케탈[(Ⅱ), R1=Tosyl]의 제조Di-3-methyl-cyclopentadecan-1-one 1,4-di-0-tosyl-2,3-D-statitol ketal [(I), R 1 = Tosyl] and L-3-methyl-cyclo Preparation of pentadecane-1-one 1,4-di-0-tosyl-2,3-D-statitol ketal [(II), R 1 = Tosyl]

상기 실시예 1에서와 같이 디메칠 디엘-무스콘 케탈(Ⅵ)을 제조한 반응액에 화합물(Ⅶ, R=Tosyl)18.07g와 벤젠 350ml와 파라톨루엔설폰산 또는 파라톨루엔설폰산 피리딘염 1㎎을 가하고 가열하여 환류시킨다.18.07 g of Compound (X, R = Tosyl), 350 ml of benzene, paratoluenesulfonic acid or paratoluenesulfonic acid pyridine salt in 1 mg of Dimethyl DL-Muscon ketal (VI) was prepared in the reaction solution. Is added and heated to reflux.

0.5∼1시간 후 반응액을 상온으로 냉각시키고 200ml의 에테르 또는 디클로로메탄으로 희석시킨 다음, 이하 실시예 1과 같은 조작을 실시하여 백색의 고체인 상기 표제화합물(Ⅰ)과 (Ⅱ)의 혼합물을 25.24g 얻었다.After 0.5 to 1 hour, the reaction solution was cooled to room temperature, diluted with 200 ml of ether or dichloromethane, and then the same procedure as in Example 1 was carried out to obtain a mixture of the title compound (I) and (II) as a white solid. 25.24 g was obtained.

이하의 재결정 조작은 실시예 1과 같은 방법으로 실시한다.The following recrystallization operation is performed by the method similar to Example 1.

[실시예 3]Example 3

디-3-메칠-시클로펜타데칸-1-온 1,4-디-0-토실-2,3-D-스테이톨 케탈[(Ⅰ), R1=Tosyl]과 엘-3-메칠-시클로펜타데칸-1-온 1,4-디-0-토실-2,3-D-스테이톨 케탈[(Ⅱ), R1=Tosyl]의 제조Di-3-methyl-cyclopentadecan-1-one 1,4-di-0-tosyl-2,3-D-statitol ketal [(I), R 1 = Tosyl] and L-3-methyl-cyclo Preparation of pentadecane-1-one 1,4-di-0-tosyl-2,3-D-statitol ketal [(II), R 1 = Tosyl]

상기 실시예 1과 같이 디메칠 디엘-무스콘 케탈(Ⅵ)을 제조하고 여기에 1,4-디-0-토실-2,3-D-스테이톨(Ⅶ, R=Tosyl)18.07g와 벤젠 600ml를 가한 다음 상온에서 1일간 교반하였다.Dimethyl DL-muscon ketal (VI) was prepared as in Example 1, and 1,4-di-0-tosyl-2,3-D-stitol (Ⅶ, R = Tosyl) was 18.07 g and benzene 600 ml was added and then stirred at room temperature for 1 day.

이 반응액을 200ml의 에테르 또는 디클로로메탄으로 희석시키고 이하의 조작을 실시예 1과 같은 동일한 방법으로 실시하여 상기 표제화합물(Ⅰ)과 (Ⅱ)의 혼합물을 25.26g 얻었다.The reaction solution was diluted with 200 ml of ether or dichloromethane and the following procedure was carried out in the same manner as in Example 1 to obtain 25.26 g of a mixture of the titled compounds (I) and (II).

이하의 재결정 조작은 실시예 1과 같은 방법으로 실시한다.The following recrystallization operation is performed by the method similar to Example 1.

[실시예 4]Example 4

디-3-메칠-시클로펜타데칸-1-온 1,4-디-0-토실-2,3-D-스테이톨 케탈[(Ⅰ), R1=Tosyl]과 엘-3-메칠-시클로펜타데칸-1-온 1,4-디-0-토실-2,3-D-스테이톨 케탈[(Ⅱ), R1=Tosyl]의 제조Di-3-methyl-cyclopentadecan-1-one 1,4-di-0-tosyl-2,3-D-statitol ketal [(I), R 1 = Tosyl] and L-3-methyl-cyclo Preparation of pentadecane-1-one 1,4-di-0-tosyl-2,3-D-statitol ketal [(II), R 1 = Tosyl]

250ml 3구 둥근플라스크에 디엘-무스콘(Ⅴ) 2.0g, 화합물(Ⅶ, R=Tosyl) 3.6g, 파라톨루엔설폰산 0.16g, 무수벤젠 100ml를 가하여 용해시킨 다음 7일동안 생성되는 물을 제거하면서, 가열·교반한 후 반응액을 상온으로 냉각하고 200ml의 에테르로 희석시키고 포화 중탄산나트륨과 소금물 순으로 세척한 다음 황산마그네슘으로 건조시키고, 감압여과하여 얻는 유기용매를 감압유거하여 상기 표제화합물(Ⅰ)과 (Ⅱ)의 혼합물을 5.4g 얻었다.To a 250 ml three-necked round flask, 2.0 g of DL-muscon (V), 3.6 g of compound (R, Tosyl), 0.16 g of paratoluenesulfonic acid, and 100 ml of anhydrous benzene were added to dissolve, and then the water produced was removed for 7 days. After heating and stirring, the reaction mixture was cooled to room temperature, diluted with 200 ml of ether, washed with saturated sodium bicarbonate and brine, dried over magnesium sulfate, and the organic solvent obtained by filtration under reduced pressure was distilled under reduced pressure to obtain the title compound ( 5.4 g of a mixture of I) and (II) was obtained.

이하의 재결정 조작은 실시예 1과 같은 방법으로 실시한다.The following recrystallization operation is performed by the method similar to Example 1.

[실시예 5]Example 5

디-3-메칠-시클로펜타데칸-1-온 1,4-디-0-벤질-2,3-D-스테이톨 케탈[(Ⅰ), R1=Benzyl]과 엘-3-메칠-시클로펜타데칸-1-온 1,4-디-0-토실-2,3-D-스테이톨 케탈[(Ⅱ), R1=Benzyl]의 제조Di-3-methyl-cyclopentadecan-1-one 1,4-di-0-benzyl-2,3-D-statitol ketal [(I), R 1 = Benzyl] and L-3-methyl-cyclo Preparation of pentadecane-1-one 1,4-di-0-tosyl-2,3-D-statitol ketal [(II), R 1 = Benzyl]

질소로 충진된 50ml 1구 플라스크에 몬트몰리노나이트 K-10 12.5g과 CH(OMe)318ml를 가하고 1시간동안 실온에서 교반한다. 미리 무수헥산 15ml에 용해시킨 디엘-무스콘(Ⅴ) 5.0g을 반응기에 가하고 1.5시간동안 실온에서 교반하여 준 다음, 감압여과하여 얻은 잔사인 몬트몰리노나이트 K-10을 무수헥산 150ml로 세척하고, 상기 유기용매와 합한 다음 감압유거하여 얻은 디메칠 디엘-무스콘 케탈(Ⅵ)에 화합물(Ⅶ, R=Benzyl) 4.7g과 디클로로메탄 13ml, 트리후루오로보란 이서레이트 0.03ml를 가한 후 실온에서 2시간동안 교반한다.To a 50 ml one-necked flask filled with nitrogen, 12.5 g of montmolinonite K-10 and 18 ml of CH (OMe) 3 were added and stirred at room temperature for 1 hour. 5.0 g of DL-muscon (V) dissolved in 15 ml of anhydrous hexane was added to the reactor and stirred at room temperature for 1.5 hours. Then, the residue obtained by filtration under reduced pressure was washed with 150 ml of anhydrous hexane. , 4.7 g of a compound (VII, R = Benzyl), 13 ml of dichloromethane, and 0.03 ml of trifururoborane isate were added to dimethyl DL-muscon ketal (VI) obtained by combining with the organic solvent and distilling under reduced pressure. Stir for 2 hours.

디클로로메탄 100ml로 희석시킨 후 물 50ml와 포화 소금물 순으로 세척하여 준 다음 황산마그네슘으로 건조시키고, 여과하여 얻은 유기용매를 감압유거하여 미황색의 기름상 물질인 하기 구조식을 갖는 화합물[(Ⅰ), R1=Benzyl]과 [(Ⅱ), R1=Benzyl]의 혼합물 8.5g을 얻었다.Dilute with 100 ml of dichloromethane, wash with 50 ml of water and saturated brine, and then dry with magnesium sulfate, filter off the organic solvent, and distillate under reduced pressure to obtain a pale yellow oily compound [(I), R 8.5 g of a mixture of 1 = Benzyl] and [(II), R 1 = Benzyl] was obtained.

이 혼합물을 MPLC를 3회 실시하여 상기 표제화합물(Ⅰ)와 (Ⅱ)화합물을 각각 4.08g(48%)을 얻었다.The mixture was subjected to MPLC three times to obtain 4.08 g (48%) of the title compound (I) and (II), respectively.

이때, 41.4㎜*250㎜의 컬럼(C18)을 사용하여 아세토니트릴-물 혼합액 85% 전개액으로, 유속은 50ml/분으로, 검출기는 자외선 254nm룰 사용하였다.At this time, the acetonitrile-water mixture was used as 85% developing solution using a 41.4mm * 250mm column ( C18 ), the flow rate was 50ml / min, and the detector used the ultraviolet-ray 254nm.

(Ⅰ), R1=Benzyl(I), R 1 = Benzyl

1H-NMR(CDCl3, ppm); 1 H-NMR (CDCl 3 , ppm);

7.31(10Ph, m), 4.57(4H3',3, s), 3.98(2H1,1', m), 3.60(4H2,2', m), 1.78-1.10(27Hring, hump), 0.95(3H, d, 7.04Hz)7.31 (10 Ph , m), 4.57 (4H 3 ', 3 , s), 3.98 (2H 1,1' , m), 3.60 (4H 2,2 ' , m), 1.78-1.10 (27H ring , hump) , 0.95 (3H, d, 7.04 Hz)

13C-NMR(CDCl3, ppm); 13 C-NMR (CDCl 3 , ppm);

CPh:138.20, 138.15, 128.28, 127.55, 127.51, 113.39(C1), 75.36(C1'), 77.30(C1), 73.45(C3'), 73.37(C3), 70.89(C2'), 70.65(C2), 44.36(C2), 37.21(C15), 36.45(C4), 28.01(C3), 21.18(C16),C Ph : 138.20, 138.15, 128.28, 127.55, 127.51, 113.39 (C 1 ), 75.36 (C 1 ' ), 77.30 (C 1 ), 73.45 (C 3' ), 73.37 (C 3 ), 70.89 (C 2 ' ), 70.65 (C 2 ), 44.36 (C 2 ), 37.21 (C 15 ), 36.45 (C 4 ), 28.01 (C 3 ), 21.18 (C 16 ),

Cring:27.31, 27.17, 26.60, 26.64, 26.61, 26.40, 26.14, 26.11, 25.05, 22.28C ring : 27.31, 27.17, 26.60, 26.64, 26.61, 26.40, 26.14, 26.11, 25.05, 22.28

IR(neat, cm-1):3088, 3064, 3030, 2927, 2858, 1947, 1872, 1807, 1740, 1497, 1455, 1029, 735, 698IR (neat, cm -1 ): 3088, 3064, 3030, 2927, 2858, 1947, 1872, 1807, 1740, 1497, 1455, 1029, 735, 698

=-3.53(c 1.0, 헥산, 100㎜) = -3.53 (c 1.0, hexane, 100 mm)

(Ⅱ), R1=Benzyl(II), R 1 = Benzyl

1H-NMR(CDCl3, ppm); 1 H-NMR (CDCl 3 , ppm);

7.31(10Ph, m), 4.58(2H3', s), 4.57(2H3, s), 4.0(2H1,1', m), 3.59(4H2,2', m), 1.81-1.09(27Hring, hump), 0.93(3H, d, 7.04Hz)7.31 (10 Ph , m), 4.58 (2H 3 ' , s), 4.57 (2H 3 , s), 4.0 (2H 1,1' , m), 3.59 (4H 2,2 ' , m), 1.81-1.09 (27H ring , hump), 0.93 (3H, d, 7.04 Hz)

13C-NMR(CDCl3, ppm); 13 C-NMR (CDCl 3 , ppm);

CPh:139.16, 128.30, 127.52, 113.51(C1), 77.88(C1'), 77.31(C1), 73.41(C3',3), 71.06(C2'), 70.80(C2), 44.80(C2), 37.06(C15), 27.96(C4), 27.35(C3), 21.36(C16),C Ph : 139.16, 128.30, 127.52, 113.51 (C 1 ), 77.88 (C 1 ' ), 77.31 (C 1 ), 73.41 (C 3', 3 ), 71.06 (C 2 ' ), 70.80 (C 2 ), 44.80 (C 2 ), 37.06 (C 15 ), 27.96 (C 4 ), 27.35 (C 3 ), 21.36 (C 16 ),

Cring:27.20, 26.80, 26.66, 26.62, 26.53, 26.31, 26.10, 25.12, 22.12C ring : 27.20, 26.80, 26.66, 26.62, 26.53, 26.31, 26.10, 25.12, 22.12

IR(neat, cm-1):3088, 3064, 3031, 2927, 2857, 1947, 1872, 1806, 1736, 1497, 1455, 1029, 735, 698IR (neat, cm -1 ): 3088, 3064, 3031, 2927, 2857, 1947, 1872, 1806, 1736, 1497, 1455, 1029, 735, 698

=7.55(c 1.0, 헥산, 100㎜) = 7.55 (c 1.0, hexane, 100 mm)

Claims (11)

하기 구조식을 갖는 화합물(Ⅰ) 또는 (Ⅱ).Compound (I) or (II) having the following structural formula. (R1=Methyl, Mesyl, Benzyl, Tosyl)(R 1 = Methyl, Mesyl, Benzyl, Tosyl) 출발물질인 화합물(Ⅴ)를 실온 또는 환류온도에서 촉매존재하 유기용매와 케탈화제를 사용하여 화합물(Ⅵ)을 제조하고, 화합물(Ⅵ)을 화합물(Ⅶ)과 케탈교환반응시켜 화합물(Ⅰ)과 (Ⅱ)의 혼합물을 제조한 다음, 유기용매로 재결정화 또는 크로마토그래피를 행하여 화합물(Ⅰ) 또는 (Ⅱ)를 분리, 제조함을 특징으로 하는 방법.Compound (VI), a starting material, was prepared at room temperature or reflux temperature using an organic solvent and a ketalizing agent in the presence of a catalyst, and compound (VI) was subjected to ketal exchange with compound (VII). And (II) to prepare a mixture, followed by recrystallization or chromatography with an organic solvent to separate and prepare Compound (I) or (II). (R=Me, Et)(R = Me, Et) (R1=Methyl, Mesyl, Benzyl, Tosyl)(R 1 = Methyl, Mesyl, Benzyl, Tosyl) 제2항에 있어서, 촉매로는 건조된 HCl, TsOH, NH4Cl, PhSO2NHOH, NaOH, La(또는, Ce, Nd, Er, Yb)Cl3, 산성이온교환수지, 몬트몰리노나이트 K-10 등을 사용할 수 있으며, 그 중에서 몬트몰리나이트 K-10를 사용함을 특징으로 하는 방법.The catalyst of claim 2, wherein the catalyst is dried HCl, TsOH, NH 4 Cl, PhSO 2 NHOH, NaOH, La (or Ce, Nd, Er, Yb) Cl 3 , acidic ion exchange resin, montmolinoite K -10 may be used, and among them, montmolinite K-10 is used. 제3항에 있어서, 촉매의 사용량은 화합물(Ⅴ)의 화합물에 대하여 중량비로 1-4배 량을 사용할 수 있으며, 그 중에서 2∼3배 량을 사용함을 특징으로 하는 방법.4. The method according to claim 3, wherein the amount of the catalyst can be used 1 to 4 times by weight with respect to the compound of compound (V), of which 2 to 3 times is used. 제2항에 있어서, 케탈화제로는 MeOH, MeOH/(MeO)4Si, Me2SO4/MeOH CH(OEt)3, CH(OMe)3등을 사용할 수 있으며, 그 중에서 CH(OEt)3또는, CH(OMe)3를 사용함을 특징으로 하는 방법.The method of claim 2, wherein the ketalizing agent may be used MeOH, MeOH / (MeO) 4 Si, Me 2 SO 4 / MeOH CH (OEt) 3 , CH (OMe) 3, etc., wherein CH (OEt) 3 Or, CH (OMe) 3 . 제5항에 있어서, 케탈화제의 사용량은 화합물(Ⅴ)의 화합물에 대하여 몰비율로 2∼10배몰을 사용할 수 있ㅇ으며, 그 중에서 4∼8배 몰을 사용함을 특징으로 하는 방법.The method of claim 5, wherein the ketalizing agent may be used in a molar ratio of 2 to 10 times the molar ratio of the compound of the compound (V), wherein a 4 to 8 times mole is used. 제2항에 있어서, 유기용매로는 극성용매인 메탄올, 에탄올, 프로필알콜 등이 사용되고, 무극성용매로는 노르말-헥산, 사염화탄소 등이 사용되며, 그 중에서 노르말-헥산을 사용함을 특징으로 하는 방법.The method of claim 2, wherein as the organic solvent, methanol, ethanol, propyl alcohol, and the like, which are polar solvents, are used, and as the nonpolar solvent, normal-hexane, carbon tetrachloride, and the like are used. 제2항에 있어서, 케탈교환반응은 산촉매하에서, 화합물(Ⅵ)을 무수벤젠에 용해시킨 다음 화합물(Ⅶ)을 가하고 가열, 용해시킨 다음 1-2시간동안 가열하거나, 또는 화합물(Ⅵ)을 유기용매에 용해시킨 다음 화합물(Ⅶ)을 가하여 실온에서 1-2시간 교반하여 완료됨을 특징으로 하는 방법.The method of claim 2, wherein the ketal exchange reaction is carried out by dissolving the compound (VI) in anhydrous benzene under an acid catalyst, followed by heating and dissolving the compound (VII), followed by heating for 1-2 hours, or by heating the organic compound (VI). Dissolving in a solvent followed by addition of compound (iii), followed by stirring for 1-2 hours at room temperature. 제2항에 있어서, 케탈교환반응이 촉매없이, 벤젠이나 극성유기용매에 화합물(Ⅵ)과 (Ⅶ)을 용해시켜 실온 또는 가열교반하여 완료됨을 특징으로 하는 방법.3. The method according to claim 2, wherein the ketal exchange reaction is completed by dissolving the compounds (VI) and (iii) in a benzene or a polar organic solvent without a catalyst and by stirring at room temperature or by heating. 제8항에 있어서, 산촉매로는 트리후루오로보란 이서레이트, 파라톨루엔설폰산, 파라톨루엔설폰산 피리딘염을 사용하며, 그 중에서 트리후루오로보란 이서레이트 또는 파라톨루엔설폰산을 사용함을 특징으로 하는 방법.9. The acid catalyst according to claim 8, wherein trifuruoroborane isomerate, paratoluenesulfonic acid, paratoluenesulfonic acid pyridine salt is used, among which trifuroboroborane isate or paratoluenesulfonic acid is used. Way. 제2항에 있어서, 화합물(Ⅰ)과 (Ⅱ)를 분리시 유기용매는 극성 또는 무극성용매 중 단복 혹은 2종 이상의 혼합용매를 사용하며, 그 중에서 특히 메탄올 또는 아세토니트릴-물 혼합액을 사용함을 특징으로 하는 방법.The organic solvent according to claim 2, wherein the organic solvent is a single or two or more mixed solvents of polar or nonpolar solvents, and in particular, methanol or acetonitrile-water mixture is used. How to.
KR1019970000044A 1997-01-04 1997-01-04 Novel synthetic intermediate of muscone and the preparation thereof KR100226622B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019970000044A KR100226622B1 (en) 1997-01-04 1997-01-04 Novel synthetic intermediate of muscone and the preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019970000044A KR100226622B1 (en) 1997-01-04 1997-01-04 Novel synthetic intermediate of muscone and the preparation thereof

Publications (2)

Publication Number Publication Date
KR19980065189A true KR19980065189A (en) 1998-10-15
KR100226622B1 KR100226622B1 (en) 1999-10-15

Family

ID=19494072

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970000044A KR100226622B1 (en) 1997-01-04 1997-01-04 Novel synthetic intermediate of muscone and the preparation thereof

Country Status (1)

Country Link
KR (1) KR100226622B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010099122A (en) * 2001-09-03 2001-11-09 김권 Resolution process for preparing l-muscone or d-muscone

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020038220A (en) * 2000-11-17 2002-05-23 여언례 Separation of l-muscone and d-muscone from muscone racemate by resolution method

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010099122A (en) * 2001-09-03 2001-11-09 김권 Resolution process for preparing l-muscone or d-muscone

Also Published As

Publication number Publication date
KR100226622B1 (en) 1999-10-15

Similar Documents

Publication Publication Date Title
JP6272888B2 (en) Process for preparing bile acid derivatives
JP2019524770A (en) Process for producing spiroketal substituted cyclic ketoenols
JP2023078126A (en) Resolution of optically active diazaspiro[4.5]decane derivatives
Schuda et al. Total synthesis of hirsutic acid C and complicatic acid
JPH0261476B2 (en)
CN103342707B (en) For the preparation of the preparation method of A Sainaping intermediate
KR100226622B1 (en) Novel synthetic intermediate of muscone and the preparation thereof
GB2036744A (en) Eburnane derivatives
KR100226621B1 (en) Novel synthetic intermediate of muscone and the preparation thereof
AU2021314375A1 (en) Method for large-scale synthesis of tetrodotoxin
SU1277897A3 (en) Method of producing 1,1-dioxo-6-brom(or-6,6-dibromine) penicillanoyloxymethyl ethers of 6-(2-azido-2-phenylacetamido)penicillanic acid
CN113372290A (en) Synthetic method of drug Tafamidis
FI77443C (en) Process for the preparation of pharmaceutically useful 1-aroyl-5-oxo-2-pyrrolidine propanoic acids and their esters.
US6392059B1 (en) Hydronaphtho[2,3-c]furan derivatives and process for the preparation thereof
KR102587674B1 (en) Process for Preparing Treprostinil
EP1458724B1 (en) Total synthesis of galanthamine, analogues and derivatives thereof
Yoshida et al. Synthesis of dl-vincadifformine, dl-eburcine and dl-3-epieburcine. Introduction of methoxycarbonyl function to c (3)-position of aspidosperma skeleton
CN115594653B (en) Polysubstituted beta-alkenyl valerolactone compound, preparation method and application
KR100256866B1 (en) Process for the preparation of l-muscone and d-muscone from d,l-muscone
CA1319698C (en) 3-alkoxy-4-thioacetoxy-2e-butenoic acid alkyl esters
RU2057140C1 (en) Method of synthesis of 6-oxa-8-isoanalogs of steroid estrogens
CN116143753A (en) NLRP3 inhibitor compounds
KR100841592B1 (en) Bezodiazole derivatives and process for preparing them
Kim Pericyclic Reaction Development and Synthetic Studies Aimed at Select Tryptamine Derived Alkaloids
CN112645977A (en) Synthesis method of de-isopropylaminophos

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120725

Year of fee payment: 14

FPAY Annual fee payment

Payment date: 20130729

Year of fee payment: 15

FPAY Annual fee payment

Payment date: 20140728

Year of fee payment: 16

LAPS Lapse due to unpaid annual fee